HMTs have the capacity to inhibit the expression of PD-L1 by increasing H3K27me3 levels on the promoters of CD274 (PD-L1 gene), potentially reducing the immune evasion capabilities of tumor cells (100). Here, CD274 is linked to neoplasm.